Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2010 1
2013 1
2014 2
2015 1
2018 1
2020 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, Siripassorn K, Ruane PJ, Berhe M, Wang H, Margot NA, Dvory-Sobol H, Hyland RH, Brainard DM, Rhee MS, Baeten JM, Molina JM; CAPELLA Study Investigators. Segal-Maurer S, et al. Among authors: siripassorn k. N Engl J Med. 2022 May 12;386(19):1793-1803. doi: 10.1056/NEJMoa2115542. N Engl J Med. 2022. PMID: 35544387 Clinical Trial.
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
Ogbuagu O, Segal-Maurer S, Ratanasuwan W, Avihingsanon A, Brinson C, Workowski K, Antinori A, Yazdanpanah Y, Trottier B, Wang H, Margot N, Dvory-Sobol H, Rhee MS, Baeten JM, Molina JM; GS-US-200-4625 investigators. Ogbuagu O, et al. Lancet HIV. 2023 Aug;10(8):e497-e505. doi: 10.1016/S2352-3018(23)00113-3. Epub 2023 Jul 11. Lancet HIV. 2023. PMID: 37451297 Clinical Trial.
Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials.
Avihingsanon A, Chetchotisakd P, Kiertiburanakul S, Ratanasuwan W, Siripassorn K, Supparatpinyo K, Martin H, Wang H, Wong T, Wang HY. Avihingsanon A, et al. Among authors: siripassorn k. HIV Med. 2023 Mar;24(3):290-300. doi: 10.1111/hiv.13386. Epub 2022 Aug 17. HIV Med. 2023. PMID: 36912172
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team. Sax PE, et al. Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15. Lancet. 2015. PMID: 25890673 Clinical Trial.
Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
Siripassorn K, Manosuthi W, Chottanapund S, Pakdee A, Sabaitae S, Prasithsirikul W, Tunthanathip P, Ruxrungtham K; Bamrasnaradura Study Team. Siripassorn K, et al. AIDS Res Hum Retroviruses. 2010 Feb;26(2):139-48. doi: 10.1089/aid.2009.0125. AIDS Res Hum Retroviruses. 2010. PMID: 20156097
Virological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine.
Siripassorn K, Manosuthi W, Pakdee A, Natprom S, Chaovavanich A, Hengphadpanadamrong N, Woratanarat K, Lueangniyomkul A, Ruxrungtham AK; Bamrasnaradura study team. Siripassorn K, et al. AIDS Res Ther. 2013 Jan 25;10(1):4. doi: 10.1186/1742-6405-10-4. AIDS Res Ther. 2013. PMID: 23347647 Free PMC article.
12 results